Analyzing vaccine purity - without an HCP ELISA

What did our LC-MS analyses of several mRNA- and protein-based vaccines for COVID-19 reveal?
A) it found that the product purity and HCP profiles vary substantially between marketed COVID-19 vaccines
B) it detected HCPs of potential concern in one of the vaccines
Watch examples of unlocking the knowledge necessary to achieve a consistent vaccine product - even within a short timeframe.